Docket No.: WIBL-P01-018
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Stockwell et al.

Application No.: 10/767591 Confirmation No.: 5216

Filed: January 29, 2004 Art Unit: 1614

For: IDENTIFICATION OF GENOTYPE-SELECTIVE AGENTS FOR TREATING HUNTINGTON'S DISEASE Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information

as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. WIBL-P01-018.

Dated: 12/19/2005

Respectfully submitted,

By _____

Z. Angela Guo
Registration No.: 54,144
ROPES & GRAY LLP
One International Place
Boston, Massachusetts 02110-2624
(617) 951-7000
(617) 951-7050 (Fax)
Attorneys/Agents For Applicant

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 4

Complete if Known	
Application Number	10/767591
Filing Date	January 29, 2004
First Named Inventor	Brent R. Stockwell
Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	WIBL-P01-018

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	CA	Ahmed, S. Ansar et al., "A new rapid and simple non-radioacive assay to monitor and determine the proliferation of lymphocytes: an alternative to [^{3}H] thymidine incorporation assay", Journal of Immunological Methods, 170(2): 211-224 (1994) (Abstract)	
	CB	Aiken, C. T., et al., "A cell-Based Screen for Drugs to Treat Huntington's Disease", Neurobiology of Disease, 16:546-555 (2004)	
	CC	Andoh, T., *et al.*, "Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I," Proc Natl Acad Sci U S A, 84:5565-5569 (1987).	
	CD	Bjornsti, M-A., *et al.*, "Expression of Human DNA Topoisomerase I in Yeast Cells Lacking Yeast DNA Topoisomerase I: Restoration of Sensitivity of the Cells to the Antitumor Drug Camptotchecin," *Cancer Res* , 49:6318-23 (1989).	
	CE	Bosch, F.X., *et al.*, "The causal relation between human papillomavirus and cervical cancer," J Clin Pathol, 55:244-265 (2002).	
	CF	Brown, E.J., et al., "A mammalian protein targeted by G1-arresting rapamycin-receptor complex," Nature, 369:756-758 (1994).	
	CG	Calin, G.A., *et al.*, "Low frequency of alterations of the α (PPP2R1A) and β (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms," Oncogene, 19:1191-1195 (2000).	
	CH	Capdeville, R., *et al.*, "Glivec (STI571, IMATINIB), A Rationally Developed, Targeted Anticancer Drug," *Nat Rev Drug Discov* , 1:493-502 (2002).	
	CI	Champoux, J.J., "Structure-Based Analysis of the Effects of Camptothecin on the Activities of Human Topoisomerase I," Annals New York Acad Sci, 922:56-64 (2000).	
	CJ	Chan, Y-M, *et al.*, "Caspase inhibitors promote the survival of avulsed spinal motoneurons in neonatal rats," *NeuroReport*, 12(3):541-5 (2001).	
	CK	D'Arpa, P., *et al.*, "Involvement of Nucleic Acid Synthesis in Cell Killing Mechanisms of Topoisomerase Poisons," *Cancer Res*, 50:6919-24 (1990).	
	CL	DeVita, V.T., Jr., *et al.*, "Principles of Cancer Management: Chemotherapy," Cancer: Principles & Practice of Oncology, Fifth Edition, 333-347 (1997).	
	CM	Dolma, S, *et al.*, "Identification of genotype-selective antitumor agents using synthetic lethal	

Examiner Signature		Date Considered	

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	4

Complete if Known	
Application Number	10/767591
Filing Date	January 29, 2004
First Named Inventor	Brent R. Stockwell
Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	WIBL-P01-018

		chemical screening in engineered human tumor cells," Cancer Cell, 3:285-296 (2003).	
	CN	Druker, B.J. et al., "Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells", Nature Medicine, 2:561-566 (1996) (Abstract)	
	CO	Elenbaas, B. et al., "Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells", Genes & Development, 15:50-65 (2001)	
	CP	Eng, W-K., *et al.*, "Evidence that DNA Topoisomerase I Is Necessary for the Cytotoxic Effects of Camptothecin," *Mol Pharmacol*, 34:755-60 (1988).	
	CQ	Hahn, W. C. and Weinberg, R. A., "Modelling the Molecular Circuitry of Cancer", Nature Reviews Cancer, 2:331-341 (2002)	
	CR	Hahn, W.C., *et al.*, "Creation of human tumour cells with defined genetic elements," Nature, 400:464-468 (1999).	
	CS	Hahn, W.C., *et al.*, "Enumeration of the Simian Virus 40 Early Region Elements Necessary for Human Cell Transformation," *Mol Cell Biol*, 22(7):2111-23 (2002).	
	CT	Hahn, W.C., *et al.*, "Inhibition of telomerase limits the growth of human cancer cells," Nat Med, 5(10):1164-1170 (1999).	
	CU	Hamad, N. M. et al., "Distinct requirements for Ras oncogenesis in human versus mouse cells", Genes & Development, 16:2045-2057 (2002)	
	CV	Harley, C.B., "Telomerases," *Pathol Biol (Paris)*, 42:342-5 (1994).	
	CW	Hsiang, Y-H. and Liu, L.F., "Identification of Mammalian DNA Topoisomerase I as an Intracellular Target of the Anticancer Drug Camptothecin," *Cancer Res*, 48:1722-6 (1988).	
	CX	Hsiang, Y-H., *et al.*, "Arrest of Replication Forks by Drug-stabilized Topoisomerase I-DNA Cleavable Complexes as a Mechanism of Cell Killing by Camptothecin," *Cancer Res*, 49:5077-82 (1989).	
	CY	Jorcyk, C.L., *et al.*, "Development and Characterization of a Mouse Prostate Adenocarcinoma Cell Line: Ductal Formation Determined by Extracellular Matrix," The Prostate, 34:10-22 (1998).	
	CZ	Kohno, T., *et al..*, "Alterations of the *PPP1R3* Gene in Human Cancer," *Cancer Res*, 59:4170-4 (1999).	
	CA1	Laurent, G. and Jaffrezou, J-P., "Signaling pathways activated by daunorubicin," Blood, 98(4):913-924 (2001).	
	CB1	Lessnick, S.L., *et al.*, "The Ewing's sarcoma oncoprotein EWS/FLI induces a p53- dependent growth arrest in primary human fibroblasts," Cancer Cell, 1:393-401 (2002).	
	CC1	Liu, L.F., *et al.*, "Mechanism of Action of Camptothecin," Annals N Y Acad Sci, 922:1-10 (2000).	
	CD1	Loomis, C.R. and Bell, R.M., "Sangivamycin, a Nucleoside Analogue, Is a Potent Inhibitor of Protein Kinase C*," J Biol Chem, 263(4):1682-1692 (1998).	
	CE1	Madden, K.R., and Champoux, J.J., "Overexpression of Human Topoisomerase I in Baby Hamster Kidney Cells: Hypersensitivity of Clonal Isolates to Camptothecin," *Cancer Res*, 52:525-32 (1992).	
	CF1	Majno, G. and Joris, I., "Apoptosis, Oncosis, and Necrosis," *Am J Pathol*, 146(1):3-15 (1995).	
	CG1	Makin, G., "Targeting apoptosis in cancer chemotherapy," *Expert Opin Ther Targets*, 6(1):73-84 (2002).	
	CH1	Miller, M.L. and Ojima, I., "Chemistry and Chemical Biology of Taxane Anticancer Agents," Chem. Record, 1:195-211 (2001).	
	CI1	Millward, T.A., *et al.*, "Regulation of protein kinase cascades by protein phosphatase 2A," Trends Biochem Sci, 24:186-91 (1999).	
	CJ1	Mokbel, K. and Hassanally, D., "From HER2 to Herceptin," *Curr Med Res Opin*, 17(1):51-9 (2001).	
	CK1	Müller, I., *et al.*, "Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity (Review), *Int J Mol Med*, 1:491-4 (1998).	

Examiner Signature		Date Considered	

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 4

Complete if Known	
Application Number	10/767591
Filing Date	January 29, 2004
First Named Inventor	Brent R. Stockwell
Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	WIBL-P01-018

	CL1	Nociari, M.M., *et al.*, "A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity," *J. Immunol. Methods*, 213:157-167 (1998).	
	CM1	Pallas, D.C., *et al*, "Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A," Cell, 60:167-176 (1990)	
	CN1	Perez-Stable, C., *et al.*, "Prostate Cancer Progression, Metastasis, and Gene Expression in Transgenic Mice," *Cancer Res*, 57:900-6 (1997).	
	CO1	Rao, K.V., "Structure of Sangivamycin," *J Med Chem*, 11:939-41 (1968).	
	CP1	Rich, J.N., *et al.*, "A Genetically Tractable Model of Human Glioma Formation," *Cancer Res*, 61:3556-60 (2001).	
	CQ1	Richard, D., *et al.*, "Free radical production and labile iron pool decrease triggered by subtoxic concentration of aclarubicin in human leukemia cell lines," Leukemia Res, 26:927-931 (2002).	
	CR1	Ruediger, R., *et al.*, "Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the Aβ subunit gene," Oncogene, 20:1892-1899 (2001).	
	CS1	Ruediger, R., *et al.*, "Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the Aα subunit gene," Oncogene, 20:10-15 (2001).	
	CT1	Sabatini, D.M., *et al.*, "RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs," Cell, 78:35-43 (1994)	
	CU1	Sandmoller, A., *et al.*, "A Transgenic Mouse Model for Lung Adenocarcinoma," *Cell Growth & Differ*, 6:97-103 (1995).	
	CV1	Schreiber, S.L., "Chemical Genetics Resulting from a Passion for Synthetic Organic Chemistry, Bioorg. Med. Chem., 6:1127-1152 (1998).	
	CW1	Sellers, W.R. and Kaelin, W.G., "Role of the retinoblastoma protein in the pathogenesis of human cancer," J Clin Oncol, 15:3301-3312 (1997).	
	CX1	Shawver, L.K., *et al.*, "Smart drugs: Tyrosine kinase inhibitors in cancer therapy," Cancer Cell, 1:117-123 (2002).	
	CY1	Sherr, C.J., "The *INK4a*/ARF Network in Tumour Suppression," Nat Rev Mol Cell Biol, 2:731-737 (2001).	
	CZ1	Shi, Y., *et al.*, "Enhanced Sensitivity of Multiple Myeloma Cells Containing *PTEN* Mutations to CCI-779," *Cancer Res*, 62:5027-34 (2002).	
	CA2	Simons, A., *et al.*, "Establishment of a Chemical Synthetic Lethality Screen in Cultured Human Cells," Genome Res, 11:266-273 (2001).	
	CB2	Stockwell, B. R., "Chemical Genetic Screening Approaches to Neurobiology," Neuron, 36:559-562 (2002).	
	CC2	Stockwell, B. R., "Frontiers in chemical genetics", Trends Biotechnol 18, 449-55, (2000)	
	CD2	Stockwell, B.R., "Chemical Genetics: Ligand-Based Discovery of Gene Function, Nat Rev Genet, 1:116-125 (2000).	
	CE2	Stockwell, B.R., "The biological magic behind the bullets," Nature Biotechnology, 22(1):37-38 (2004).	
	CF2	Stockwell, B.R., *et al.*, "High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications," Chem Biol, 6:71-83 (1999).	
	CG2	Testa, J.R. and Giordano, A., "SV40 and cell cycle perturbations in malignant mesothelioma," Seminars In Cancer Biol, 11:31-8 (2001).	
	CH2	Torrance, C.J., *et al.*, "Use of isogenic human cancer cells for high-throughput screening and drug discovery," Nat Biotechnol, 19:940-945 (2001).	
	CI2	Traganos, F., *et al.*, "Induction of Apoptosis by Camptothecin and Topotecan," *Ann N Y Acad Sci*, 803:101-10 (1996).	
	CJ2	Tsao, Y-P., *et al.*, "Interaction between Replication Forks and Topoisomerase I-DNA Cleavable Complexes: Studies in a Cell-free SV40 DNA Replication System," *Cancer Res*,	

Examiner Signature		Date Considered	

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 4

Complete If Known	
Application Number	10/767591
Filing Date	January 29, 2004
First Named Inventor	Brent R. Stockwell
Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	WIBL-P01-018

		53:5908-14 (1993).	
	CK2	Van Dyke, M, M. and Dervan, Peter B., "Echinomycin Binding Sites on DNA", Science 225:1122-1127 (1984)	
	CL2	Vonsattel J.P.G., "Neuropathology of Huntington's Disease," *Neuroscience News*, 3(2-3):45-53 (2000).	
	CM2	Wang, S.S., *et al.*, "Alterations of the *PPP2R1B* Gene in Human Lung and Colon Cancer," Science, 282:284-287 (1998).	
	CN2	Wang, X. M. et al., "A new microcellular cytotoxicity test based on calcein AM release", Human Immunology, 37(4):264-270 (1993) (Abstract)	
	CO2	Waring, M.J. and Wakelin, L.P.G., "Echinomycin: a bifunctional intercalating antibiotic," *Nature*, 252:653-7 (1974).	
	CP2	Weinstein, J.N., *et al*, "An Information-Intensive Approach to the Molecular Pharmacology of Cancer," Science, 275:343-349 (1997).	
	CQ2	Zalacain, M., *et al.*, "The mode of action of the antitumor drug bouvardin, an inhibitor of protein synthesis in eukaryotic cells," FEBS Lett, 148(1):95-97 (1982).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	

PTO/SB/92 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Application No. (if known): 10/767018 Attorney Docket No.: WIBL-P01-011

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on 12/19/05 .
Date

Signature

Typed or printed name of person signing Certificate

Registration Number, if applicable

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS by Applicant – Form PTO/SB/08 (69 References)
References (69, CA – CQ2)